SCI Abstract

search
+
Rucaparib induces mitochondrial fragmentation and apoptosis in prostate cancer cells by targeting Drp1
Rucaparib induces mitochondrial fragmentation and apoptosis in prostate cancer cells by targeting Drp1
Mitochondrial dynamics, particularly the balance between fission and fusion, are critical in regulating cellular metabolis...
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes
As monotherapy, PARP inhibitors have little cytotoxic effect in tumors without homologous recombinant repair (HRR) alterat...
Comparative analysis of the effects of PSPH and PHGDH inhibitors on tumor cell proliferation
Comparative analysis of the effects of PSPH and PHGDH inhibitors on tumor cell proliferation
Serine metabolism plays a pivotal role in supporting the rapid proliferation of tumor cells, with PHGDH recognized as a ke...
Advanced strategies to overcome multidrug resistance in cancer therapy: progress in P-glycoprotein inhibitors, drug delivery, and personalized medicine
Advanced strategies to overcome multidrug resistance in cancer therapy: progress in P-glycoprotein inhibitors, drug delivery, and personalized medicine
Multidrug resistance (MDR) appears to be a major challenge in cancer treatment, frequently leading to suboptimal clinical ...
Association of different approvals with Chinese Society of Clinical Oncology recommendation levels for solid tumor drugs: a cross-sectional analysis
Association of different approvals with Chinese Society of Clinical Oncology recommendation levels for solid tumor drugs: a cross-sectional analysis
In China, many solid tumor drugs have been approved via the accelerated approval (AA) pathway. We extracted data regarding...
Targeting the TRIB3–MYC axis in cancer: mechanistic insights and therapeutic disruption strategies
Targeting the TRIB3–MYC axis in cancer: mechanistic insights and therapeutic disruption strategies
The oncogenic transcription factor MYC drives proliferation, metabolism, and therapy resistance in the majority of human c...
Targeting the Keap1/Nrf2 axis in cancer: molecular mechanisms and pharmacological interventions
Targeting the Keap1/Nrf2 axis in cancer: molecular mechanisms and pharmacological interventions
The transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) is the first-line regulator of a plethora of c...
Safety and efficacy of semi-dose venetoclax plus azacitidine in unfit acute myeloid leukemia patients in China: a real-world single-center study
Safety and efficacy of semi-dose venetoclax plus azacitidine in unfit acute myeloid leukemia patients in China: a real-world single-center study
Acute myeloid leukemia (AML) carries a poor prognosis in elderly or medically unfit patients, with median overall survival...
Evaluation of the anti-leukemia activity and underlying mechanisms of the novel perinucleolar compartment inhibitor CTI-2 in acute myeloid leukemia
Evaluation of the anti-leukemia activity and underlying mechanisms of the novel perinucleolar compartment inhibitor CTI-2 in acute myeloid leukemia
Acute myeloid leukemia (AML) is a malignant clonal hematological tumor originating from immature myeloid cells and is the ...
Direct functional HOXA9/DNA-binding competitors versus epigenetic inhibitors of HOXA9 expression on cell proliferation, death and differentiation processes in the model of MLL-rearranged acute myeloid leukemia
Direct functional HOXA9/DNA-binding competitors versus epigenetic inhibitors of HOXA9 expression on cell proliferation, death and differentiation processes in the model of MLL-rearranged acute myeloid leukemia
Recent progress in cancer treatment has led to the development of advanced therapies targeting specific oncogenic drivers,...
Synergistic effects of the curcumin analog HO-3867 and olaparib in transforming fallopian tube epithelial cells
Synergistic effects of the curcumin analog HO-3867 and olaparib in transforming fallopian tube epithelial cells
Ovarian cancer remains one of the most lethal gynecologic malignancies, largely due to high recurrence rates and treatment...
Anti-CD47 tri-specific killer engager enhances NK cell cytotoxicity against lung cancer
Anti-CD47 tri-specific killer engager enhances NK cell cytotoxicity against lung cancer
Lung cancer remains the leading cause of cancer-related deaths worldwide, with immune evasion posing a major therapeutic c...
Clinical characteristics, treatment and prognosis of pembrolizumab induced myocarditis
Clinical characteristics, treatment and prognosis of pembrolizumab induced myocarditis
To explore the regularity and clinical characteristics of pembrolizumab induced myocarditis, and to provide a reference fo...
The multifaceted role of KIF15 in cancer progression and therapy
The multifaceted role of KIF15 in cancer progression and therapy
Kinesin family member 15 (KIF15), a kinesin superfamily motor protein, is known to be involved in mitotic spindle formatio...
Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor–relapsed tumors
Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor–relapsed tumors
We report a phase 1/2 study evaluating EDP1503 (capsule containing Bifidobacterium animalis lactis) ± pem...
Tackling tumor hypoxia: advances in breaking the oncogenic HIF-1α–p300/CBP alliance
Tackling tumor hypoxia: advances in breaking the oncogenic HIF-1α–p300/CBP alliance
The ability of tumor cells to survive under low-oxygen conditions is largely attributed to the hypoxia-inducible factor-1 ...
Clinical potential of antibody–drug conjugates in early-phase clinical trials for late-line treatment of advanced solid tumors
Clinical potential of antibody–drug conjugates in early-phase clinical trials for late-line treatment of advanced solid tumors
Recently, comprehensive genomic profiling (CGP)-matched therapy and antibody–drug conjugates (ADCs) have garnered in...
Assessing the risks and benefits of investigational new drugs in adult phase-I oncology trials in China, 2013–2021
Assessing the risks and benefits of investigational new drugs in adult phase-I oncology trials in China, 2013–2021
Previous research shows that the benefits of phase-I oncology trials increased from 5 to 18% between 2000 and 2019 globall...
Beyond the obvious: targeting the SLC transportome and non-canonical drug transport mechanisms in cancer therapy
Beyond the obvious: targeting the SLC transportome and non-canonical drug transport mechanisms in cancer therapy
The solute carrier (SLC) superfamily comprises a broad array of membrane-bound transport proteins that are integral to the...
Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial
Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial
The RELAY-Brain trial examined the clinical utility and survival impacts of ramucirumab (RAM) combined with epidermal grow...
Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer
Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer
Due to the emergence of drug resistance, androgen receptor (AR)-targeted drugs still pose great challenges in the treatmen...
Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study
Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study
The combination therapy of lenvatinib and immunotherapy as first-line treatment remains controversial in unresectable hepa...
Comprehensive study of gene fusions in sarcomas
Comprehensive study of gene fusions in sarcomas
Sarcomas, including bone sarcomas and soft tissue sarcomas (STSs), are a heterogeneous group of mesenchymal malignancies. ...
A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer
A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer
Antiangiogenic drugs may cause vascular normalization and correct hypoxia in tumors, shifting cells to mitochondrial respi...
Deficiency of myeloid discoidin domain receptor 2 aggravates melanoma lung and bone metastasis
Deficiency of myeloid discoidin domain receptor 2 aggravates melanoma lung and bone metastasis
Melanoma, one of the most prevalent cancers worldwide, frequently metastasizes to the lung and bones. Tumor-associated mac...
DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanoma
DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanoma
Dynein cytoplasmic 2 heavy chain 1 (DYNC2H1) is reported to play a potential role in cancer immunotherapy. However, the as...
Efficacy and safety of fruquintinib plus capecitabine as first-line treatment in patients with metastatic colorectal cancer ineligible for intravenous chemotherapy: a two-stage, single-armed, phase II study
Efficacy and safety of fruquintinib plus capecitabine as first-line treatment in patients with metastatic colorectal cancer ineligible for intravenous chemotherapy: a two-stage, single-armed, phase II study
Fruquintinib has been recommended for treating refractory metastatic colorectal cancer. This single-arm, phase II study ex...
HDAC6 inhibition through WT161 synergizes with temozolomide, induces apoptosis, reduces cell motility, and decreases β-catenin levels in glioblastoma cells
HDAC6 inhibition through WT161 synergizes with temozolomide, induces apoptosis, reduces cell motility, and decreases β-catenin levels in glioblastoma cells
Glioblastoma multiforme (GBM) accounts for 70% of all primary malignancies of the central nervous system. Current treatmen...
Cardioprotective effects of PARP inhibitors for platinum-agent induced cardiotoxicity
Cardioprotective effects of PARP inhibitors for platinum-agent induced cardiotoxicity
Poly(ADP-ribose) polymerase (PARP) inhibitors may have cardioprotective properties. This study aimed to evaluate the poten...
Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response
Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response
Colorectal cancer is the third most prevalent cancer in the world. Early screening and detection of tumours, active surgic...
Load More
format_indent_increase